TWiV 811: COVID-19 clinical update #82 with Dr. Daniel Griffin
About this episode
In COVID-19 clinical update #82, Daniel Griffin reviews vaccines for 5-12 years old, safety of a third vaccine dose, Oklahoma reinfection data, Regencov outcomes, Pfizer protease inhibitor, impact of Tocilizumab, and incidence of long COVID.
Hosts: Daniel Griffin and Vincent Racaniello
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Data on Pfizer-BioNTech in 5-12 year olds (Pfizer)
- Safety of additional vaccine dose (MMWR)
- Oklahoma reinfection rates (OK DOH)
- Regencov outcomes (NEJM)
- Pfizer protease inhibitor trial (Pfizer)
- WHO recommends antibody therapy (Hosp Health)
- Tocilizumab use in hospitalized patients (Resp Care)
- Long COVID (PLoS Medicine)
- Letters read on TWiV 811
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]
Get every episode summarized
Each time This Week in Virology publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from This Week in Virology
TWiV 1309: Maybe they're all cancer vaccines
This Week in Virology
TWiV 1308: Clinical update with Dr. Daniel Griffin
This Week in Virology
TWiV 1307: My heart breaks for flu
This Week in Virology
TWiV 1306: Clinical update with Dr. Daniel Griffin
This Week in Virology